



07-01-04

IFW

EXPRESS MAIL NO.: EV 452 772 876 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux *et al.*

Confirmation No.: 9582

Application No.: 10/743,950

Group Art Unit: 1642

Filed: December 24, 2003

Examiner: To Be Assigned

For: SULFIDE AND DISULFIDE
COMPOUNDS AND COMPOSITIONS
FOR CHOLESTEROL MANAGEMENT
AND RELATED USES

Attorney Docket No.: 10173-112-999
(CAM No.: 371855-999107)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A25**, **B01-B07** and **C01-C38** which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant."

Copies of References **A01-A25**, **B01-B07** and **C01-C38** are not being submitted pursuant to 37 C.F.R. §1.98(d) since these references were made of record in prior application Serial No. 09/976,898, filed October 11, 2001, of which this application claims priority under 35 U.S.C. §120.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants request that the Examiner review all the references identified on the attached Form PTO-1449, and that they be made of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(b)(3) before the mailing date of a first Office Action on the merits, Applicants

estimate that no fee is required. Should a fee be required, the Commissioner is authorized to charge such fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

By: Michael J. Bruner, Reg. No. 47,458

Date June 29, 2004

By: Michael J. Bruner (Reg. No. 47,458)

For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY

222 East 41st Street

New York, New York 10017

(858) 314-1130

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY DOCKET NO.

10173-112-999

APPLICATION NO

10/743,950

APPLICANT

Dasseux et al.

FILING DATE

December 24, 2003

GROUP

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,143,755	11/7/00	Bocan			
	A02	6,124,309	9/26/00	Bocan			
	A03	6,093,719	7/25/00	Bocan			
	A04	6,093,744	7/25/00	Lee et al.			
	A05	6,017,905	1/25/00	Roark et al.			
	A06	5,981,595	11/9/99	Picard et al.			
	A07	5,968,963	10/19/99	Homan			
	A08	5,783,600	6/21/98	Bisgaier et al.			
	A09	5,756,344	5/26/98	Onda et al.			
	A10	5,756,544	5/26/98	Bisgaier et al.			
	A11	5,750,569	5/12/98	Bisgaier et al.			
	A12	5,648,387	7/15/97	Bisgaier et al.			
	A13	5,633,287	5/27/97	Lee et al.			
	A14	5,578,639	11/26/96	Homan			
	A15	5,504,073	4/2/96	Homan			
	A16	5,502,198	3/26/96	Picard et al.			
	A17	5,093,370	3/3/92	Kimura et al.			
	A18	4,711,896	12/8/87	Bar-Tana et al.			
	A19	4,689,344	8/25/87	Bar-Tana			
	A20	4,634,719	1/6/87	Takaishi et al.			
	A21	4,613,593	9/23/86	Yamatsu et al.			
	A22	4,584,321	4/22/86	Manghisi et al.			
	A23	4,287,200	9/1/81	Kawamatsu et al.			
	A24	3,930,024	12/30/75	Creger			
	A25	3,773,946	11/20/73	Creger			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	DE 44 36 578	4/18/96	Germany				
	B02	EP 0 366 205	5/2/90	Europe				
	B03	EP 0 084 720	8/3/83	Europe				
	B04	EP 0 032 063	12/30/80	Europe				
	B05	WO 99/00116	1/7/99	PCT				
	B06	WO 98/30530	7/16/98	PCT				
	B07	WO 96/30328	10/3/96	PCT				

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

	Acton et al., 1996, "Identification of scavenger receptor SR BI as a high density lipoprotein receptor," <i>Science</i> 271 :518-520
C02	Badimon et al., 1992, "Role of high density lipoproteins in the regression of atherosclerosis," <i>Circulation</i> 86 (Suppl. III):86-94
C03	Barrans et al., 1996, "Pre beta HDL: structure and metabolism," <i>Biochem. Biophys Acta</i> 1300 :73-85
C04	Bellaart et al; Metal Complexes of 4, 7-Dithiadecane-1,10-dicarboxylic Acid and Allied Compounds; <i>Z. anorg. Allg. Chem.</i> 412 , 155-160 (1975)
C05	Bisgaier et al., 1998, "A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor," <i>J. Lipid Res.</i> 39 :17-30; (1998)
C06	Brown and Goldstein, 1990, "Drugs used in the treatment of hyperlipoproteinemias," In: <i>The Pharmacological Basis of Therapeutics</i> , 8th Ed., Goodman & Gilman, eds., Pergamon Press, Ch. 36, pp. 874-896
C07	Bruce et al., 1998, "Plasma lipid transfer proteins, high density lipoproteins, and reverse cholesterol transport," <i>Annu. Rev. Nutr.</i> 18 :297-330
C08	Chaussade et al; X-ray Crystal Structure of a Novel Alkoxide-bridged dimolybdenum complex; <i>Bull. Soc. Chim. Fr.</i> (1995) 132 , 265-267
C09	Dansky and Fisher, 1999, "High density lipoprotein and plaque regression: the good cholesterol gets even better," <i>Circulation</i> 100 :1762-1763
C10	Decossin et al., 1997, "Subclasses of LpA-I in coronary artery disease: distribution and cholesterol efflux ability," <i>Eur. J. Clin. Invest.</i> 27 :299-307
C11	Dingwall et al.; Free Radical Catalysed Additions to the Double Bond of Diketene: A Synthesis of Novel Oxetan-2-ones; <i>J. Chem. Soc. Perkin Trans, I</i> 1986
C12	Fielding and Fielding, 1995, "Molecular physiology of reverse cholesterol transport," <i>J. Lipid Res.</i> 36 :211-228
C13	Gearing et al., 1993, "Interaction of the peroxisome proliferator activated receptor and retinoid X receptor," <i>Proc. Natl. Acad. Sci. USA</i> 90 :1440-1444
C14	Harris and Kletzien, 1994, "Localization of a pioglitazone response element in the adipocyte fatty acid binding protein gene," <i>Mol. Pharmacol.</i> 45 :439-445
C15	Heyman et al., 1992, "9-cis retinoic acid is a high affinity ligand for the retinoid X receptor," <i>Cell</i> 68 :397-406
C16	Hidaka and Fidge, 1992, "Affinity purification of the hepatic high density lipoprotein receptor identifies two acidic glycoproteins and enables further characterization of their binding properties," <i>Biochem. J.</i> 284 :161-167
C17	Hirano et al., 1997, "Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity," <i>Arterioscler. Thromb. Vasc. Biol.</i> 17 :1053-1059
C18	Issemann and Green, 1990, "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators," <i>Nature</i> 347 :645-650
C19	Keller and Wahli, 1993, "Peroxisome proliferator-activated receptors - a link between endocrinology and nutrition," <i>TEM</i> 4 :291-296
C20	Keller et al., 1993, "Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator activated receptor retinoid X receptor heterodimers," <i>Proc. Natl. Acad. Sci. USA</i> 90 :2160-2164
C21	Kliwer et al., 1992, "Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors," <i>Nature</i> 358 :771-774
C22	Kurata et al., 1998, "A candidate high density lipoprotein (HDL) receptor, HB ₂ , with possible multiple functions shows sequence homology with adhesion molecules," <i>J. Atheroscler. and Thromb.</i> 4 :112-117
C23	Lagrost et al., 1996, "Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients," <i>J. Biol. Chem.</i> 271 :19058-19065
C24	Landschulz et al., 1996, "Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat," <i>J. Clin. Invest.</i> 98 :984-995
C25	Lazarow and Fujiki, 1985, "Biogenesis of peroxisomes," <i>Annu. Rev. Cell Biol.</i> 1 :489-530
C26	Levin et al., 1992, "9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR α ," <i>Nature</i> 355 :359-361
C27	Mcguire et al; Peroxisome Induction Potential and Lipid-regulating Activity in Rats; <i>American Journal of Pathology</i> , Vol. 139, No. 1, July 1, 1991, pgs. 217-229
C28	Nemali et al., 1988, "Comparison of constitutive and inducible levels of expression of peroxisomal β oxidation and catalase genes in liver and extrahepatic tissues of rat," <i>Cancer Res.</i> 48 :5316-5324
C29	Parra et al., 1992, "A case control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study," <i>Arterioscler. Thromb.</i> 12 :701-707
C30	Reaven, 1993, "Role of insulin resistance in human disease (syndrome X): an expanded definition," <i>Annu. Rev. Med.</i> 44 :121-131
C31	Reddy and Lalwani, 1983, "Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans," <i>Crit. Rev. Toxicol.</i> 12 :1-58

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C32	Rigotti et al., 1996, "Regulation by adrenocorticotrophic hormone of the in vivo expression of scavenger receptor class B type I (SR BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland," J. Biol. Chem. <u>271</u> :33545-33549
C33	Robins and Fasulo, 1997, "High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile," J. Clin. Invest. <u>99</u> :380-384
C34	Skinner et al; Gastric Ulcer Presenting As Gastroesophageal Reflux and Apnea in a Term Neonate; Tex Medic., <u>94</u> (9):57-58 (1998)
C35	Staels and Auwerx, 1998, "Regulation of apo A-I gene expression by fibrates," Atherosclerosis <u>137</u> (Suppl.):S19-S23
C36	Tontonoz et al., 1994, "Adipocyte specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR γ and RXR α ," Nucl. Acids Res. <u>22</u> :5628-5634
C37	Vamecq and Draye, 1989, "Pathophysiology of peroxisomal β -oxidation," Essays Biochem. <u>24</u> :115-225
C38	Yoshida et al; Ruthenium(II) hydrido complexes of quadridentate crown thioethers,"; Journal of Organometalli Chemistry, <u>473</u> (1994) pp 225-241.

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.